Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.38
OREX's Cash-to-Debt is ranked lower than
75% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. OREX: 0.38 )
Ranked among companies with meaningful Cash-to-Debt only.
OREX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.38  Med: 19.71 Max: No Debt
Current: 0.38
Equity-to-Asset 0.21
OREX's Equity-to-Asset is ranked lower than
92% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. OREX: 0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
OREX' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.15  Med: 0.36 Max: 0.86
Current: 0.21
-3.15
0.86
Piotroski F-Score: 1
Altman Z-Score: -1.63
Beneish M-Score: 11.79
WACC vs ROIC
14.08%
-68.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -108.81
OREX's Operating Margin % is ranked lower than
88% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. OREX: -108.81 )
Ranked among companies with meaningful Operating Margin % only.
OREX' s Operating Margin % Range Over the Past 10 Years
Min: -107754.55  Med: -3403.74 Max: -54.99
Current: -108.81
-107754.55
-54.99
Net Margin % -71.59
OREX's Net Margin % is ranked lower than
86% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. OREX: -71.59 )
Ranked among companies with meaningful Net Margin % only.
OREX' s Net Margin % Range Over the Past 10 Years
Min: -105954.55  Med: -3422.74 Max: -67.59
Current: -71.59
-105954.55
-67.59
ROE % -57.58
OREX's ROE % is ranked lower than
88% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. OREX: -57.58 )
Ranked among companies with meaningful ROE % only.
OREX' s ROE % Range Over the Past 10 Years
Min: -246.53  Med: -116.89 Max: -42.04
Current: -57.58
-246.53
-42.04
ROA % -5.65
OREX's ROA % is ranked lower than
76% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. OREX: -5.65 )
Ranked among companies with meaningful ROA % only.
OREX' s ROA % Range Over the Past 10 Years
Min: -101.77  Med: -58 Max: -5.65
Current: -5.65
-101.77
-5.65
ROC (Joel Greenblatt) % -10.93
OREX's ROC (Joel Greenblatt) % is ranked lower than
75% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. OREX: -10.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OREX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -34518.01  Med: -5974.94 Max: -10.93
Current: -10.93
-34518.01
-10.93
3-Year Revenue Growth Rate 56.70
OREX's 3-Year Revenue Growth Rate is ranked higher than
96% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. OREX: 56.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OREX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 56.7 Max: 227.2
Current: 56.7
0
227.2
3-Year EBITDA Growth Rate -29.00
OREX's 3-Year EBITDA Growth Rate is ranked lower than
92% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. OREX: -29.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OREX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -49.8  Med: -24.4 Max: -8
Current: -29
-49.8
-8
3-Year EPS without NRI Growth Rate -25.70
OREX's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. OREX: -25.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OREX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -55.4  Med: -23.3 Max: -8.7
Current: -25.7
-55.4
-8.7
GuruFocus has detected 6 Warning Signs with Orexigen Therapeutics Inc $OREX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OREX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OREX Guru Trades in Q1 2016

Seth Klarman 22,268,399 sh (+881.68%)
Jim Simons 2,381,100 sh (+34.81%)
Paul Tudor Jones 76,473 sh (-24.61%)
» More
Q2 2016

OREX Guru Trades in Q2 2016

Seth Klarman 22,268,399 sh (unchged)
Jim Simons 549,500 sh (-76.92%)
Paul Tudor Jones 12,073 sh (-84.21%)
» More
Q3 2016

OREX Guru Trades in Q3 2016

Seth Klarman 2,226,839 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q4 2016

OREX Guru Trades in Q4 2016

Seth Klarman 2,226,839 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:VRX » details
Traded in other countries:JXS1.Germany,
Orexigen Therapeutics Inc is a biopharmaceutical company. The Company is engaged in development of pharmaceutical product candidates for the treatment of obesity. Its product candidate includes NB32 and Empatic.

Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity.

Ratios

vs
industry
vs
history
PB Ratio 0.77
OREX's PB Ratio is ranked higher than
93% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. OREX: 0.77 )
Ranked among companies with meaningful PB Ratio only.
OREX' s PB Ratio Range Over the Past 10 Years
Min: 0.35  Med: 5.42 Max: 1446.67
Current: 0.77
0.35
1446.67
PS Ratio 2.75
OREX's PS Ratio is ranked higher than
50% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. OREX: 2.75 )
Ranked among companies with meaningful PS Ratio only.
OREX' s PS Ratio Range Over the Past 10 Years
Min: 1.2  Med: 137.15 Max: 3995.83
Current: 2.75
1.2
3995.83
Current Ratio 4.17
OREX's Current Ratio is ranked higher than
73% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. OREX: 4.17 )
Ranked among companies with meaningful Current Ratio only.
OREX' s Current Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.62 Max: 19.3
Current: 4.17
1.99
19.3
Quick Ratio 3.81
OREX's Quick Ratio is ranked higher than
75% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. OREX: 3.81 )
Ranked among companies with meaningful Quick Ratio only.
OREX' s Quick Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.62 Max: 19.3
Current: 3.81
1.99
19.3
Days Inventory 1.00
OREX's Days Inventory is ranked higher than
99% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. OREX: 1.00 )
Ranked among companies with meaningful Days Inventory only.
OREX' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1
Current: 1
0
1
Days Sales Outstanding 30.93
OREX's Days Sales Outstanding is ranked higher than
86% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. OREX: 30.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
OREX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.2  Med: 16.9 Max: 101.89
Current: 30.93
8.2
101.89
Days Payable 1.00
OREX's Days Payable is ranked lower than
99% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. OREX: 1.00 )
Ranked among companies with meaningful Days Payable only.
OREX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1
Current: 1
0
1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.90
OREX's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. OREX: -19.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OREX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -178.3  Med: -26.3 Max: -19.9
Current: -19.9
-178.3
-19.9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.02
OREX's Price-to-Median-PS-Value is ranked higher than
100% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. OREX: 0.02 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OREX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.07 Max: 29.94
Current: 0.02
0.02
29.94
Earnings Yield (Greenblatt) % -4.67
OREX's Earnings Yield (Greenblatt) % is ranked lower than
78% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. OREX: -4.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OREX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.74  Med: 77.1 Max: 2085.3
Current: -4.67
-4.74
2085.3

More Statistics

Revenue (TTM) (Mil) $24.76
EPS (TTM) $ -3.28
Beta2.61
Short Percentage of Float28.27%
52-Week Range $1.65 - 6.49
Shares Outstanding (Mil)14.62

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 33 87
EPS ($) -9.70 -6.72
EPS without NRI ($) -9.70 -6.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OREX

Headlines

Articles On GuruFocus.com
Seth Klarman’s Largest New Buys and Adds Feb 15 2016 
Value Investing in BioPharma Nov 18 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 

More From Other Websites
OREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 30 2017
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y Mar 29 2017
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y Mar 29 2017
Edited Transcript of OREX earnings conference call or presentation 28-Mar-17 9:00pm GMT Mar 28 2017
Orexigen reports 4Q loss Mar 28 2017
Orexigen reports 4Q loss Mar 28 2017
Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today Mar 28 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 28 2017
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31,... Mar 28 2017
Orexigen Inks Commercialization Deal for Contrave, Stock Up Mar 28 2017
Q4 2016 Orexigen Therapeutics Inc Earnings Release - Before Market Open Mar 28 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno... Mar 27 2017
How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and... Mar 20 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 08 2017
Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016... Mar 07 2017
Biotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and... Feb 27 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Feb 24 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results... Feb 17 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 09 2017
Orexigen Therapeutics to Speak at Upcoming Investor Conferences Feb 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)